{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-020973","form_type":"8-K","ticker":"PTIX","cik":"0001022899","company_name":"Protagenic Therapeutics, Inc.new","filed_at":"2024-05-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.924025+00:00","generated_at":"2026-06-01T09:34:31.896744+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Protagenic Therapeutics reports zero clinically-relevant adverse events in Phase 1 single dose portion for PT00114","bullets":["Phase 1 single dose trial completed with 30 subjects across five cohorts up to 1,000 micrograms; no clinically-relevant adverse events.","Multiple ascending dose portion of the trial is planned to commence later this year.","PT00114 targets stress reduction as root cause for PTSD, depression, anxiety, addiction, and potentially obesity.","Investor call scheduled for May 22 at 10:00 am ET to discuss safety data and implications."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-020973","json":"https://secwatch.observer/filing/0001493152-24-020973.json","markdown":"https://secwatch.observer/filing/0001493152-24-020973.md","text":"https://secwatch.observer/filing/0001493152-24-020973.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1022899/000149315224020973/0001493152-24-020973-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1022899/000149315224020973/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T09:34:31.896744+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}